SFRP5 and metabolic dysfunction-associated steatohepatitis: When we analyzed the gene expression in VAT, we found higher SFRP5 mRNA expression in SS and NASH patients than NL (Figure 6A); but, when the SS group was disaggregated, the enhanced expression of SFRP5 was observed in mild SS stage and in NASH compared with NL group (Figure 6B).